| First Author | Choi J | Year | 2024 |
| Journal | iScience | Volume | 27 |
| Issue | 9 | Pages | 110642 |
| PubMed ID | 39252970 | Mgi Jnum | J:358808 |
| Mgi Id | MGI:7732917 | Doi | 10.1016/j.isci.2024.110642 |
| Citation | Choi J, et al. (2024) Etomoxir repurposed as a promiscuous fatty acid mimetic chemoproteomic probe. iScience 27(9):110642 |
| abstractText | Etomoxir has been used for decades as a popular small molecule inhibitor of carnitine palmitoyltransferase I, Cpt1, to block mitochondrial fatty acid beta-oxidation. To test the specificity of etomoxir, we generated click chemistry-enabled reagents to label etomoxir binding proteins in situ. Etomoxir bound to Cpt1, but also bound to a large array of diverse proteins that metabolize and transport fatty acids in the cytoplasm, peroxisome, and mitochondria. Many of the most abundant proteins identified in primary hepatocytes were peroxisomal proteins. The loss of Pex5, required for the import of peroxisomal matrix proteins, eliminated many of these etomoxir-labeled proteins. By utilizing the promiscuous, covalent, and fatty acid mimetic properties of etomoxir, etomoxir targets of fatty acid omega-oxidation were revealed following the loss of Pex5. These data demonstrate that etomoxir is not specific for Cpt1 and is not appropriate as a tool to distinguish the biological effects of fatty acid oxidation. |
